{"title":"利巴韦林治疗发病30年后伴有抗博纳病病毒1抗体的重度精神分裂症","authors":"Hidenori Matsunaga, Akio Fukumori, Kohji Mori, Takashi Morihara, Shunsuke Sato, Kyoko Kitauchi, Kanta Yanagida, Kazumi Taguchi, Tomoyuki Honda, Keizo Tomonaga","doi":"10.1155/2023/4899364","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Borna disease virus 1 (BoDV-1) was proven to cause fatal encephalitis in humans in 2018. However, the effects of persistent infections remain unclear. Here, we present the case of a 50-year-old woman with a 30-year history of severe schizophrenia, who was exposed to fleas from stray cats prior to disease onset, suggesting the possibility of zoonosis including BoDV-1 infection. The patient had experienced significant social impairment, thought deterioration, delusions, and hallucinations for more than 20 years.</p><p><strong>Method: </strong>A radioligand assay was used to test the patient for IgG and IgM antibodies against BoDV-1 nucleoprotein (N) and phosphoprotein (P). Based on the protocol for hepatitis C, we treated the patient with 400 mg/day ribavirin, which was later increased to 600 mg/day.</p><p><strong>Results: </strong>The serological examination revealed anti-BoDV-1 N IgG. Although only subtle changes were observed over the 24 weeks of treatment, the family noticed that the patient's Cotard delusions had disappeared 7 months after completing the treatment, accompanied by some improvements in the relationship with the family.</p><p><strong>Conclusion: </strong>Though definite proof was not obtained, this presumed suppression of BoDV-1 by ribavirin leading to improvements in Cotard syndrome-like symptoms suggests that intractable schizophrenia might be one of the BoDV-1 infection phenotypes. Further studies are needed to clarify the effect of persistent BoDV-1 infections in humans.</p>","PeriodicalId":9631,"journal":{"name":"Case Reports in Psychiatry","volume":"2023 ","pages":"4899364"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988380/pdf/","citationCount":"1","resultStr":"{\"title\":\"Ribavirin Treatment for Severe Schizophrenia with Anti-Borna Disease Virus 1 Antibodies 30 Years after Onset.\",\"authors\":\"Hidenori Matsunaga, Akio Fukumori, Kohji Mori, Takashi Morihara, Shunsuke Sato, Kyoko Kitauchi, Kanta Yanagida, Kazumi Taguchi, Tomoyuki Honda, Keizo Tomonaga\",\"doi\":\"10.1155/2023/4899364\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Borna disease virus 1 (BoDV-1) was proven to cause fatal encephalitis in humans in 2018. However, the effects of persistent infections remain unclear. Here, we present the case of a 50-year-old woman with a 30-year history of severe schizophrenia, who was exposed to fleas from stray cats prior to disease onset, suggesting the possibility of zoonosis including BoDV-1 infection. The patient had experienced significant social impairment, thought deterioration, delusions, and hallucinations for more than 20 years.</p><p><strong>Method: </strong>A radioligand assay was used to test the patient for IgG and IgM antibodies against BoDV-1 nucleoprotein (N) and phosphoprotein (P). Based on the protocol for hepatitis C, we treated the patient with 400 mg/day ribavirin, which was later increased to 600 mg/day.</p><p><strong>Results: </strong>The serological examination revealed anti-BoDV-1 N IgG. Although only subtle changes were observed over the 24 weeks of treatment, the family noticed that the patient's Cotard delusions had disappeared 7 months after completing the treatment, accompanied by some improvements in the relationship with the family.</p><p><strong>Conclusion: </strong>Though definite proof was not obtained, this presumed suppression of BoDV-1 by ribavirin leading to improvements in Cotard syndrome-like symptoms suggests that intractable schizophrenia might be one of the BoDV-1 infection phenotypes. Further studies are needed to clarify the effect of persistent BoDV-1 infections in humans.</p>\",\"PeriodicalId\":9631,\"journal\":{\"name\":\"Case Reports in Psychiatry\",\"volume\":\"2023 \",\"pages\":\"4899364\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988380/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/4899364\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/4899364","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
摘要
目的:2018年证实博尔纳病病毒1型(BoDV-1)可引起人类致死性脑炎。然而,持续感染的影响尚不清楚。在这里,我们报告了一名50岁的女性,她有30年的严重精神分裂症病史,她在发病前曾接触过流浪猫身上的跳蚤,这表明她可能患有人畜共患病,包括BoDV-1感染。20多年来,患者经历了严重的社交障碍、思维恶化、妄想和幻觉。方法:采用放射配体法检测患者抗BoDV-1核蛋白(N)和磷蛋白(P)的IgG和IgM抗体。根据丙型肝炎治疗方案,我们给患者服用400 mg/d的利巴韦林,后来增加到600 mg/d。结果:血清学检查显示抗bodv -1 N IgG。虽然在24周的治疗中只观察到细微的变化,但患者的家人注意到,患者的科塔尔妄想在完成治疗7个月后消失了,与家人的关系也有所改善。结论:虽然没有明确的证据,但利巴韦林对BoDV-1的抑制导致了科塔尔综合征样症状的改善,这表明难治性精神分裂症可能是BoDV-1感染表型之一。需要进一步的研究来阐明人类持续BoDV-1感染的影响。
Ribavirin Treatment for Severe Schizophrenia with Anti-Borna Disease Virus 1 Antibodies 30 Years after Onset.
Objective: Borna disease virus 1 (BoDV-1) was proven to cause fatal encephalitis in humans in 2018. However, the effects of persistent infections remain unclear. Here, we present the case of a 50-year-old woman with a 30-year history of severe schizophrenia, who was exposed to fleas from stray cats prior to disease onset, suggesting the possibility of zoonosis including BoDV-1 infection. The patient had experienced significant social impairment, thought deterioration, delusions, and hallucinations for more than 20 years.
Method: A radioligand assay was used to test the patient for IgG and IgM antibodies against BoDV-1 nucleoprotein (N) and phosphoprotein (P). Based on the protocol for hepatitis C, we treated the patient with 400 mg/day ribavirin, which was later increased to 600 mg/day.
Results: The serological examination revealed anti-BoDV-1 N IgG. Although only subtle changes were observed over the 24 weeks of treatment, the family noticed that the patient's Cotard delusions had disappeared 7 months after completing the treatment, accompanied by some improvements in the relationship with the family.
Conclusion: Though definite proof was not obtained, this presumed suppression of BoDV-1 by ribavirin leading to improvements in Cotard syndrome-like symptoms suggests that intractable schizophrenia might be one of the BoDV-1 infection phenotypes. Further studies are needed to clarify the effect of persistent BoDV-1 infections in humans.